Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...

Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...

Pathmaker's MyoRegulator is designed to ease hyperexcitability and delivers an electrical current to the spinal cord and ...

A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in ...

A simple treatment algorithm to aid in the selection of appropriate DMTs reduces racial disparities in patients with ...

Clene will join APST Research to explore how CNM-Au8 affects NfL levels in ALS patients treated in expanded access programs.

WASHINGTON — Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly fivefold to $35.8 billion between 2019 and 2023, a U.S. government watchdog's ...

A recent study shows that computer algorithms can be used to find molecules that can be developed into anti-inflammatory ...

This effort aims to support the potential accelerated approval of Clene's investigational drug CNM-Au8 for ALS treatment. According to InvestingPro data, the company is currently burning through cash ...

Whakatāne man Rhys Drayson, pictured in 2019, has terminal cancer but says being part of a trial for drugs that are soon to be funded by Pharmac has extended his life. A Whakatāne man with ...